Tudor Investment Corp ET AL lowered its position in shares of Baxter International Inc. (NYSE:BAX) by 21.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,876 shares of the medical instruments supplier’s stock after selling 7,035 shares during the period. Tudor Investment Corp ET AL’s holdings in Baxter International were worth $1,342,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Pure Financial Advisors Inc. raised its position in shares of Baxter International by 0.3% in the first quarter. Pure Financial Advisors Inc. now owns 7,459 shares of the medical instruments supplier’s stock worth $387,000 after buying an additional 22 shares during the last quarter. Quadrant Capital Group LLC raised its position in shares of Baxter International by 1.3% in the first quarter. Quadrant Capital Group LLC now owns 2,344 shares of the medical instruments supplier’s stock worth $113,000 after buying an additional 31 shares during the last quarter. Dumont & Blake Investment Advisors LLC raised its position in shares of Baxter International by 0.3% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 12,786 shares of the medical instruments supplier’s stock worth $663,000 after buying an additional 40 shares during the last quarter. Livingston Group Asset Management CO operating as Southport Capital Management raised its position in shares of Baxter International by 0.3% in the first quarter. Livingston Group Asset Management CO operating as Southport Capital Management now owns 18,079 shares of the medical instruments supplier’s stock worth $938,000 after buying an additional 54 shares during the last quarter. Finally, Reliance Trust Co. of Delaware raised its position in shares of Baxter International by 1.1% in the first quarter. Reliance Trust Co. of Delaware now owns 5,743 shares of the medical instruments supplier’s stock worth $298,000 after buying an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 84.09% of the company’s stock.

Baxter International Inc. (BAX) opened at 62.67 on Friday. The company has a 50-day moving average price of $60.23 and a 200 day moving average price of $53.80. Baxter International Inc. has a 52-week low of $43.13 and a 52-week high of $63.14. The stock has a market cap of $34.07 billion, a price-to-earnings ratio of 18.55 and a beta of 0.66.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Wednesday, April 26th. The medical instruments supplier reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.07. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.43 billion. Baxter International had a net margin of 18.09% and a return on equity of 14.03%. Baxter International’s quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.36 EPS. On average, analysts expect that Baxter International Inc. will post $2.27 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Shareholders of record on Friday, September 1st will be issued a $0.16 dividend. The ex-dividend date is Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a yield of 1.02%. Baxter International’s payout ratio is 19.05%.

TRADEMARK VIOLATION NOTICE: “Baxter International Inc. (NYSE:BAX) Shares Sold by Tudor Investment Corp ET AL” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/07/22/baxter-international-inc-nysebax-shares-sold-by-tudor-investment-corp-et-al.html.

A number of brokerages have recently weighed in on BAX. Royal Bank Of Canada raised their price objective on Baxter International from $55.00 to $58.00 and gave the company a “sector perform” rating in a research report on Thursday, April 27th. BMO Capital Markets restated a “hold” rating and set a $55.00 price objective on shares of Baxter International in a research report on Thursday, April 27th. Zacks Investment Research lowered Baxter International from a “hold” rating to a “sell” rating in a research report on Wednesday, April 5th. Cantor Fitzgerald began coverage on Baxter International in a research report on Thursday, June 29th. They set an “overweight” rating and a $70.00 price objective for the company. Finally, Barclays PLC raised their price objective on Baxter International from $62.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, June 14th. One analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Baxter International currently has a consensus rating of “Buy” and a consensus price target of $61.54.

In other news, SVP Brik V. Eyre sold 130,732 shares of the stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $55.69, for a total value of $7,280,465.08. Following the completion of the sale, the senior vice president now owns 49,966 shares of the company’s stock, valued at approximately $2,782,606.54. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Carole J. Shapazian sold 2,618 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $57.92, for a total transaction of $151,634.56. Following the completion of the sale, the director now directly owns 9,848 shares of the company’s stock, valued at approximately $570,396.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 137,110 shares of company stock valued at $7,642,246. 0.05% of the stock is owned by insiders.

About Baxter International

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.